Clinical Trial

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2019 (before its estimated January 1, 2022 completion). Its status may not reflect the trial's current state.
Summary
The study aims to compare the efficacy and safety of S-1 for 9 months versus S-1 for 1 year as adjuvant chemotherapy after D2 resection in patients with gastric cancer. Hypothesis: For gastric patients after D2 resection, S-1 for 9 months shows non-inferiority to S-1 for 1 year in disease-free survival(DFS), overall survival (OS) and safety.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-05-06; most recent amendment 2019-05-29.
Trial Details
NCT Number NCT03941561
Lead Sponsor Fudan University
Conditions Gastric Cancer
Enrollment 1,006 participants
Start Date 2019-01-01
Primary Completion 2022-01-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2019-05-31